Valion Bio, Inc. (TIVC) Form 8-K — May 14, 2026
Valion Bio reported a net loss of $6.2 million for the first quarter of 2026, its first full quarter under the new corporate identity following the rebrand from Tivic Health Systems. The loss reflects increased operating expenses of $5.6 million, driven by the integration of its wholly owned manufacturing subsidiary Velocity Bioworks and continued advancement of its Entolimod platform. Cash and cash equivalents stood at $7.2 million at the end of the quarter, down from $12.6 million at the end of 2025, indicating a cash burn rate of approximately $5.4 million per quarter. The company highlighted ongoing engagement with U.S.
Key figures
- Total Debt
- 6899000
- Total Assets
- 38215000
- Cash Position
- 7215000
- Operating Expenses
- 5634000
- Weighted Average Shares
- 2883650
- Operating Expenses Prior Year
- 1377000
Price after filing
Close on the filing date to close N calendar days later (from $0.93). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.